#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glycogen storage disease type V Exudative retinopathy Keratosis follicular Gestational trophoblastic tumour Ehlers-Danlos syndrome Autoimmune hepatitis Neuronal ceroid lipofuscinosis Myxofibrosarcoma Primitive neuroectodermal tumour Parkinson's disease Hereditary angioedema with C1 esterase inhibitor deficiency Ornithine transcarbamoylase deficiency Hyperadrenocorticism Bone marrow disorder Oesophageal achalasia More trials…

    Learn about Rare Diseases

    Leiomyosarcoma metastatic – Life with Disease Glycogen storage disease type V Inclusion body myositis Haemophilia B with anti factor IX – Basic Information Wiskott-Aldrich syndrome – Trials in Disease Cholangitis sclerosing – Basic Information Castleman’s disease – Diagnostics Myelodysplastic syndrome – Treatment Lymphangiosarcoma Pelizaeus-Merzbacher disease – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Leniolisib Phosphate Vh4524184 Mps-103 GSK3862995B ATTR-01 AZD0292 Darolutamide Fludrocortisone Rbl007.2 Deucravacitinib Brexucabtagene Autoleucel Poractant Alfa ALG-000184 Teriparatide Ruxolitinib Rosnilimab Levothyroxine Rasagiline Ds-2325A Vitamin A Bp More therapies…

    Learn about Your Condition

    Malignant melanoma stage III Indolent systemic mastocytosis Incisional hernia Leiomyosarcoma Interstitial lung disease Catatonia Hereditary optic atrophy Anal cancer stage II Triple negative breast cancer Noninfective chorioretinitis Embolism venous Essential hypertension Liposarcoma metastatic Infantile spasms Urticaria cholinergic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone
    Belgium France

  • Study on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    • Acute myeloid leukaemia
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • INOBRODIB
    • Teclistamab
    • Daratumumab
    Spain

  • Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone Ph. Eur.
    • Daratumumab
    Austria Belgium Czechia France Germany Greece +5

  • Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Elranatamab
    • Lenalidomide
    France

  • Study of IDP-121 for Patients with Relapsed or Refractory Multiple Myeloma, B-cell Lymphoma, or Chronic Lymphocytic Leukemia

    Recruiting

    2 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • Chronic lymphocytic leukaemia
    • Plasma cell myeloma
    Investigated Drugs:
    • IDP-121
    Spain

  • Study on Reducing Oral Side Effects of Talquetamab in Multiple Myeloma Patients Using Pregabalin, Dexamethasone, and Clonazepam

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Clonazepam
    • Tacrolimus Monohydrate
    • Pregabalin
    The Netherlands Spain
Previous Page
1 2 3 4 5 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!